Expert Scientific Advisory Committee (ESAC)

MMV’s Expert Scientific Advisory Committee (ESAC) helps to identify the best projects worthy of inclusion in the portfolio and continues to monitor progress through an annual review of all projects. This committee consists of experts from both industry and academia and covers the full range of expertise required to assess projects that are engaging in the extremely complex process of drug research and development.

ESAC Members

Dr Aileen Allsop

Dr Salim Abdullah Director, Ifakara Health Institute, Tanzania

Prof Kelly Chibale Founder and Director, University of Cape Town, Drug Discovery and Development Centre (H3-D), South Africa

Dr Robert Clay Consultant, Highbury Regulatory Science Limited and Chief Regulatory Officer, Kinapse Ltd.

Prof Simon Croft Professor of Parasitology and Head of the Department of Infectious and Tropical Diseases, LSHTM, UK

Prof Umberto D'Alessandro Theme Leader Disease Control and Elimination, Medical Research Council, The Gambia

Prof Ogobara Doumbo Director, Malaria Research and Training Center, Bamako, Mali

Dr Michael Dunne Chief Medical Officer, Durata Therapeutics, USA

Prof Paul Fish Chair of Medicinal Chemistry, University College London, UK

Dr Kasturi Haldar Professor, Julius Nieuwland Chair of Biological Sciences, Director, Center for Rare and Neglected Diseases, University of Notre Dame, USA

Prof Dennis Kyle Distinguished University Health Professor, College of Public Health, University of South Florida, USA

Dr Trevor Laird Managing Director/Owner, Scientific Update, UK

Prof John Lambert Chief Medical Officer, Global Head Medical Affairs and Consulting, PAREXEL International – Early Phase, UK

Dr Mary Mader Senior Research Advisor, Discovery Chemistry Research and Technologies, Eli Lilly and Company, USA

Dr Michael Makanga Director South-South Cooperation and Head of Africa Office, European and Developing Countries Clinical Trials Partnership, South Africa     

Dr Christine Manyando, Head of Public Health Department, Tropical Diseases Research Centre, Ndola, Zambia      

Dr David McGibney Pharmaceutical Research and Development Expert; Consultant Pharmaceutical Physician; and Co-Chairman MMV ESAC (Development)

Dr George K Mooney KGM Pharma Consulting LLC, USA

Prof François Nosten MD; Director, Shoklo Malaria Research Unit; and part of the Wellcome Trust–Mahidol–Oxford University Tropical Medicine Research Programme, Thailand

Dr Bernhards Ogutu Researcher, Kenya Medical Research Institute, Kenya

Dr Paul Reider, Pharmaceutical Specialist and Lecturer, Department of Chemistry, Princeton University, NJ, USA          

Dr David Roberts Independent Scientific Consultant, Congleton, UK

Dr Dennis Schmatz former Vice President, Head of Tsukuba Research Institute, Merck-Banyu Research Laboratories, Japan; and Co-Chairman MMV ESAC (Discovery)

Dr Peter Siegl Director, Siegl Pharma Consulting LLC, PA, USA

Dr Per Sjoberg Partner, Eureda, Sweden

Prof Dennis Smith former Vice President, PGRD, Pfizer, Kent, UK

Prof Terrie Taylor MD and Distinguished Professor, University of Michigan, MI, USA

Dr Neena Valecha Director, National Institute of Malaria Research, New Delhi, India

Dr Thomas Wellems Chief, Laboratory of Malaria and Vector Research (LMVR), National Institute of Allergy and Infectious Diseases, USA

Dr Matthew Wyvratt Senior Vice President, Drug Discovery, Motif BioSciences, Inc., New York, USA